It was announced that pharmaceutical company Renovia Inc. will move forward with a variety of new products used to treat pelvic floor disorders. Pelvic floor disorders are a group of conditions that affect the pelvic floor, including, the muscles, ligaments and connective tissue in the lower part of the pelvis. The pelvic flood supports your bowel, bladder, uterus, vagina, and rectum. It helps these organs function properly.
Renovia Inc. CEO Marc Beer established the company to diagnose, treat, and improve the lives of millions of women. They specialize in precise and cost effective visualization and treatment for weakened pelvic floor muscles. They restore pelvic health by strengthening the pelvic floor muscles and treating underlying pelvic floor disorders. This is done with a combination of innovative FDA approved medical management systems that help patients take back control of their pelvic floor muscles. There medical devices and mobile app utilizes micro sensors and Bluetooth tools provide enhanced technology that tracks the progress of the pelvic floor.
In August Renovia Inc. CEO Marc Beer announced that his company was closing a $32 million Series B round, along with $10 million in venture debt. The Boston based company MedTech, made the announcement that they were in the process of developing a variety of diagnostic and therapeutic products used to treat pelvic floor disorders, such as incontinence. Incontinence is an issue that affects over 200 million women worldwide.
Renovia’s first product Leva is a revolutionary, state of the art, FDA cleared pelvic training device that uses interactive technology that can empower you to improve pelvic strength with pelvic floor muscle therapy, without the dangers of surgery, or the side effects of medication. It was approved by the FDA in April. The firm,
The Longwood Fund is an early investor in Renovia, and joined the series B round. The funding will go towards the development and testing of a new generation Leva device. It will help improve the lives of millions of women suffering with pelvic floor disorders.
Marc Beer is also known for founding Viacell, a biotechnology company that specializes in the preservation and development of umbilical cord blood stem cells. He served as its CEO until 2007. He also served as Vice-President of the global marketing for company Genzyme Therapeutics Worldwide, and VP of sales and marketing for Biostar, Inc. He is a former member of the Massachusetts Science Board. He currently serves on Good Start Genetics board of directors. Mr. Beer brings has over twenty years of experience in the biotechnology field. Learn more : https://www.slideshare.net/MarcBeer